Key figures of biosimilar medicines in France

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Key figures of biosimilar medicines in France

Home/Reports | Posted 30/09/2022 0 Post your comment

At the online session of BIOS 22, Biosimilar medicines: changing patient care pathways, changing outcomes, speaker Nadia Amer, Health Economist Analyst at the Health Product Department in the Caisse Nationale d’Assurance Maladie (CNAM) in France, delivered a presentation based on concrete examples and experiences of biosimilar medicines in France [1].

Her presentation included some key figures about the biosimilar market in France. Biosimilars turnover is growing very rapidly. It had been multiplied by 5.6 times over the past five years and it reached Euros 1.6 billion in 2021. More than half of turnover is generated by hospital (54%) and community pharmacies (46%). Biosimilars represent almost half (48%) of the biological market and a 3% of the total pharmaceutical market.

However, and despite these growing numbers, the penetration rate is quite low with 25% on average measured as volume share of drugs delivered in the community whether prescribed by hospital- or community-based practitioners, see Figure 1,. This is far from the objective of 80% that was to be achieved by 2023.

Figure 1: Heterogenous penetration rate (volume share, community)

In a series of the next two articles, the incentives and challenges of biosimilar medicines in France will be discussed.

Related articles
Challenges of biosimilar medicines in France

Incentives promoting use of biosimilar medicines in France

Competition from biosimilars drives price reductions for biologicals in France

The cost-effectiveness of biosimilars

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: La EMA pide la intercambiabilidad de los biosimilares en toda la UE

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: La EMA pide la intercambiabilidad de los biosimilares en toda la UE

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Reference
1. Biosimilar medicines: changing patient care pathways, changing outcomes. Webinar BIOS 22. 28 April 2022, Thursday. Speaker: Nadia Amer, Health Economics Analyst, Health Product Department, Caisse Nationale d’Assurance Maladie (CNAM), France.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: CNAM 2021 data